//Generics --> https://generics.citeline.com

Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz International GmbH


Latest From Sandoz International GmbH

Sandoz And Bio-Thera Get EU Nod For Bevacizumab

At its May meeting, the EMA’s CHMP has issued positive opinions for Sandoz and Bio-Thera’s Avzivi partnered biosimilar rival to Avastin, as well as five generics that included a trio of pomalidomide products.

Approvals Biosimilars

Dr Reddy’s Strikes $67m Deal With Alvotech On Denosumab

Dr Reddy’s has announced a denosumab licensing deal with Alvotech covering the US and Europe, for which the Indian company has broken down the financial details. More broadly, the alliance will also allow Dr Reddy’s to build up its commercial infrastructure for biosimilars in both key markets.

Deals Biosimilars

Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay

With Sandoz delivering first-quarter growth thanks to its booming biosimilars business – and despite flat sales of small-molecule generics that suffered from a downturn in North America – the company is “well on track to surf the biosimilars wave,” according to one analyst. However, Sandoz did report a delay to progress with its natalizumab biosimilar in the US that will push back launch.

Sales & Earnings Biosimilars

Lupin Enters Canadian Biosimilars Market With Etanercept

Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.

Biosimilars Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs